According to a regulatory statement, AstraZeneca Pharma India intends to sell its Bengaluru manufacturing site. As part of its ongoing strategic evaluation, the business aims to quit the Bengaluru manufacturing site in due course. AstraZeneca Pharma acknowledges that their primary obligation is to their employees.

"AstraZeneca Pharma India Limited (Company) remains committed to advancing access to innovative medicines in India, with a clear ambition to be scientific pioneers, leaders in specialist disease areas, and change patient outcomes." "AstraZeneca intends to exit the manufacturing site in Bangalore in due course as part of its ongoing strategic review of its Global Manufacturing and Supply Network," the company stated in a filing.

The company will fully operationally position the manufacturing facility for sale and begin its hunt for a buyer who can also function as a Contract Manufacturing Organisation (CMO) for the items currently made or packaged at the Bengaluru site. AztraZeneca admitted that the proposals are subject to statutory authorization.

Further, it said, "The company is fully cognizant of the impact this change can bring and its first responsibility will be towards its employees and meeting the needs of its patients by ensuring an uninterrupted supply of medicines."

AstraZeneca India was founded in 1979 and is located in Bengaluru. The listed operational firm is AstraZeneca Pharma India Limited (AZPIL), which is a subsidiary of AstraZeneca Plc, UK. According to their website, AstraZeneca India employs around 1,400 people across the country.

AstraZeneca Pharma India focuses on the discovery, development, and commercialization of prescription medications, primarily in the oncology, cardiology, renal, metabolic, and respiratory therapy sectors.